Targeting Super-Enhancers Suppresses Cancer Stemness and Invasion of HNSCC
靶向超级增强剂抑制癌症干细胞和 HNSCC 的侵袭
基本信息
- 批准号:10404040
- 负责人:
- 金额:$ 39.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:Amino Acid MotifsBMI1 geneBindingBiological AssayBromodomainCellsCervical lymph node groupChIP-seqChemoresistanceColorectal CancerCombination Drug TherapyCommon NeoplasmComplexCyclin-Dependent KinasesDNA Polymerase IIDNA-Directed RNA PolymeraseDevelopmentEnhancersEpigenetic ProcessExhibitsFamily memberGene ExpressionGene TargetingGenesGenetic TranscriptionGenomic SegmentGenomicsGrowthHead and Neck CancerHead and Neck Squamous Cell CarcinomaHead and neck structureHistone H3Histone H4HistonesHumanImpairmentIndividualLeadLysineMalignant Epithelial CellMalignant NeoplasmsMediator of activation proteinMetastatic Neoplasm to Lymph NodesMichiganMolecularMutationNeck CancerNeoplasm MetastasisNeurofibrillary TanglesNitroquinolinesOncogenesOncogenicOral cavityOropharyngealOxidesPatientsPlayPrognosisProtein FamilyProteinsReaderRelapseResistanceResistance developmentRoleSubgroupSurvival RateTestingTissuesTranscriptTranscription ElongationTranscription InitiationTranscriptional ActivationTranscriptional RegulationTumor Cell InvasionUniversitiesbasecancer cellcancer stem cellcancer therapycofactoreffective therapygenetic approachimprovedin vivoinhibitormalignant breast neoplasmmouse modelnovelnovel strategiesnovel therapeutic interventionnovel therapeuticspatient derived xenograft modelpreventprotein degradationrecruitself-renewalstemnesstherapeutic targettranscription factortranscriptome sequencingtreatment strategytumortumor growthtumorigenic
项目摘要
The long-term objectives of this application are to understand how super-enhancers (SEs) control the
invasive growth and metastasis of head and neck squamous cell carcinoma (HNSCC) and to develop novel
therapeutics for HNSCC. HNSCC is highly invasive and resistant to cancer therapy and frequently metastasizes
to cervical lymph node, and patients with HNSCC have poor prognosis compared to other cancers such as
breast and colorectal cancers. Therefore, novel effective therapies need to be developed for HNSCC patients.
SEs are a genomic region that consists of multiple enhancers which are collectively bound by a set of
transcription factors and epigenetic readers to drive transcription of genes associated with cell identity.
Bromodomain-containing protein 4 (BRD4) is one of the four bromodomain and extra-terminal motif (BET)
protein family members. In SEs, BRD4 functions as an epigenetic reader that recognizes and interacts with
acetylated lysine residues on histone H3 and H4. Upon binding to the acetylated histones, BRD4 recruits the
Mediator complex, the cyclin-dependent kinase 7 (CDK7) complex, and other factors to facilitate transcription
initiation and elongation. Growing evidence suggests that SEs preferentially regulated the transcription of key
oncogenes in various cancers which can be selectively inhibited by BET inhibitors (BETi). To explore whether
SEs are a therapeutic target for HNSCC, we performed preliminary studies to characterize SEs in HNSCC, and
discovered that SEs selectively controlled the transcription of a set of oncogenic genes associated with cancer
stemness and invasion in addition to some common tumor-promoting genes. Using the newly-established
mouse model of HNSCC that allows us to trace cancer stem cells (CSCs) in vivo, we found that disruption of SEs
by BETi could potently eliminate CSCs and inhibit HNSCC invasive growth in vivo. We also showed that the new
BET degrader (BETd) potently inhibited the expression of cancer stemness and pro-invasive genes by inducing
BET family protein degradation. Based on these exciting preliminary studies, in this application, we hypothesize
that SEs control the expression of cancer stemness and pro-invasive genes, and targeting SEs by BETd might
help to eliminate CSCs and block tumor cell invasion, thereby improving anti-tumor efficacy and preventing
lymph node metastasis of HNSCC. To test our hypothesis, we propose the following three specific aims: 1)
Determine whether disruption of SEs suppresses tumor invasive growth and metastasis and effectively
eliminates CSCs in a mouse model of HNSCC; 2) Determine whether the disruption of SEs inhibits the
self-renewal, tumorigenic potentials and metastasis of CSCs isolated from human HNSCC; and 3) Determine
how SEs are assembled in HNSCC and explore the molecular mechanisms by which disruption of SEs inhibits
cancer stemness and invasion of HNSCC. Novel findings from our studies may lead to the development of novel
strategies for the treatment of human HNSCC.
本应用程序的长期目标是了解超级增强剂(SES)如何控制
头部和颈部鳞状细胞癌(HNSCC)的侵入性生长和转移
HNSCC的治疗剂。 HNSCC具有高度侵入性,对癌症疗法具有抗药性,并且经常转移
与其他癌症(例如
乳腺癌和结直肠癌。因此,需要为HNSCC患者开发新的有效疗法。
SES是一个由多个增强子组成的基因组区域
转录因子和表观遗传读取器驱动与细胞身份相关的基因的转录。
含溴构域的蛋白4(BRD4)是四个溴结构域和末端基序之一(BET)之一
蛋白质家族成员。在SES中,BRD4充当表观遗传学读者,识别并与
组蛋白H3和H4上的乙酰化赖氨酸残基。与乙酰化组蛋白结合后,BRD4招募了
介体复合物,依赖细胞周期蛋白的激酶7(CDK7)复合物以及其他因素以促进转录
启动和伸长。越来越多的证据表明,SES优先调节了密钥的转录
在各种癌症中的癌基因,可以被BET抑制剂选择性抑制(BETI)。探索是否
SES是HNSCC的治疗靶标,我们进行了初步研究以表征HNSCC中的SES,并进行了初步研究。
发现SES选择性控制了与癌症相关的一组致癌基因的转录
除了一些常见的肿瘤基因外,干性和侵袭。使用新建立的
允许我们在体内追踪癌症干细胞(CSC)的HNSCC的小鼠模型,我们发现SES的破坏
BETI可以有效地消除CSC并抑制体内HNSCC侵入性生长。我们还表明了新的
BET DEGRADER(BETD)通过诱导,有效抑制癌症的表达和促侵入性基因
BET家族蛋白降解。基于这些令人兴奋的初步研究,在本应用中,我们假设
SES控制了癌症的表达和促侵入性基因,而BETD靶向SES可能
帮助消除CSC并阻止肿瘤细胞侵袭,从而提高抗肿瘤功效并防止
HNSCC的淋巴结转移。为了检验我们的假设,我们提出以下三个特定目的:1)
确定SES的破坏是否抑制肿瘤的侵入性生长和转移,并有效地
消除HNSCC小鼠模型中的CSC; 2)确定SES的破坏是否抑制
从人类HNSCC分离的CSC的自我更新,致瘤潜力和转移; 3)确定
如何在HNSCC中组装SE并探索SES抑制的分子机制
HNSCC的癌症和入侵。我们研究的新发现可能导致新颖的发展
治疗人类HNSCC的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CUN-YU WANG其他文献
CUN-YU WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CUN-YU WANG', 18)}}的其他基金
Epigenetic regulation of autophagy and stemness of MSCs in skeletal aging
骨骼衰老过程中间充质干细胞自噬和干性的表观遗传调控
- 批准号:
10901048 - 财政年份:2023
- 资助金额:
$ 39.36万 - 项目类别:
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
通过靶向 KDM4A 抑制 HNSCC 的生长和转移
- 批准号:
10180628 - 财政年份:2021
- 资助金额:
$ 39.36万 - 项目类别:
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
通过靶向 KDM4A 抑制 HNSCC 的生长和转移
- 批准号:
10442655 - 财政年份:2021
- 资助金额:
$ 39.36万 - 项目类别:
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
通过靶向 KDM4A 抑制 HNSCC 的生长和转移
- 批准号:
10615200 - 财政年份:2021
- 资助金额:
$ 39.36万 - 项目类别:
Molecular and Epigenetic Control of Wnt/b-catenin-mediated oncogenesis by KDM4B
KDM4B 对 Wnt/b-catenin 介导的肿瘤发生的分子和表观遗传控制
- 批准号:
10543816 - 财政年份:2020
- 资助金额:
$ 39.36万 - 项目类别:
Targeting Super-Enhancers Suppresses Cancer Stemness and Invasion of HNSCC
靶向超级增强剂抑制癌症干细胞和 HNSCC 的侵袭
- 批准号:
10618847 - 财政年份:2020
- 资助金额:
$ 39.36万 - 项目类别:
Targeting Super-Enhancers Suppresses Cancer Stemness and Invasion of HNSCC
靶向超级增强剂抑制癌症干细胞和 HNSCC 的侵袭
- 批准号:
10224169 - 财政年份:2020
- 资助金额:
$ 39.36万 - 项目类别:
Molecular and Epigenetic Control of Wnt/b-catenin-mediated oncogenesis by KDM4B
KDM4B 对 Wnt/b-catenin 介导的肿瘤发生的分子和表观遗传控制
- 批准号:
9892322 - 财政年份:2020
- 资助金额:
$ 39.36万 - 项目类别:
Molecular and Epigenetic Control of Wnt/b-catenin-mediated oncogenesis by KDM4B
KDM4B 对 Wnt/b-catenin 介导的肿瘤发生的分子和表观遗传控制
- 批准号:
10332761 - 财政年份:2020
- 资助金额:
$ 39.36万 - 项目类别:
Epigenetic Regulation of Orofacial Bone Homeostasis and Aging by KDM4B
KDM4B 对口面部骨稳态和衰老的表观遗传调控
- 批准号:
9636222 - 财政年份:2018
- 资助金额:
$ 39.36万 - 项目类别:
相似国自然基金
高血糖介导BMI1基因异常活化诱导DNA CpG岛去甲基化促进糖尿病肾病的作用和机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
高血糖介导BMI1基因异常活化诱导DNA CpG岛去甲基化促进糖尿病肾病的作用和机制研究
- 批准号:82100895
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
改邪归正:癌基因HLF在Bmi1驱动肝内胆管癌发生中的抑癌作用研究
- 批准号:82073091
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
BMI1基因表达对多发性骨髓瘤相关巨噬细胞的调控作用研究
- 批准号:81800207
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
BMI1和KLF4双信号通路阻滞在骨肉瘤干细胞的自我更新和肺转移中的作用及机制研究
- 批准号:81772867
- 批准年份:2017
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
The Center for Synovial Sarcoma Biology and Therapeutics
滑膜肉瘤生物学和治疗中心
- 批准号:
10797558 - 财政年份:2023
- 资助金额:
$ 39.36万 - 项目类别:
PRC1-dependent H2A Monoubiquitination During Human Corticogenesis
人类皮质生成过程中 PRC1 依赖性 H2A 单泛素化
- 批准号:
10604561 - 财政年份:2023
- 资助金额:
$ 39.36万 - 项目类别:
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer
靶向抑制 eIF5Ahpu 可抑制口腔癌中的肿瘤生长和 M2 样 TAM 极化
- 批准号:
10573290 - 财政年份:2022
- 资助金额:
$ 39.36万 - 项目类别:
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer
靶向抑制 eIF5Ahpu 可抑制口腔癌中的肿瘤生长和 M2 样 TAM 极化
- 批准号:
10441837 - 财政年份:2022
- 资助金额:
$ 39.36万 - 项目类别: